CytomX Therapeutics Company Overview 2016

CytomX Therapeutics presents its Probody antibody-drug conjugate platform designed to enhance tumor targeting in cancer immunotherapy. The company outlines its pipeline strategy, including clinical-stage candidates CX-072 (PD-L1) and CX-2009 (CD166), alongside key milestones and financial position with $180 million cash balance through 2018.